Wal-mart Pharmacy 10-2194 | |
5885 Kingstowne Blvd, Alexandria, Virginia 22315 | |
(703) 924-8805 |
Name | Wal-mart Pharmacy 10-2194 |
---|---|
Organization Name | Wal-mart Stores East Lp |
Location | 5885 Kingstowne Blvd, Alexandria, Virginia 22315 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Phone | (703) 924-8805 |
Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
Sepsis presents a major challenge for health care providers, especially in low-income countries where the mortality rate can exceed 60 percent.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
NPI Number | 1629095724 |
Organization Name | WAL-MART STORES EAST LP |
Doing Business As | WAL-MART PHARMACY 10-2194 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Address | 5885 Kingstowne Blvd, Alexandria, VA 22315 |
Phone Number | 703-924-8805 |
News Archive
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
Sepsis presents a major challenge for health care providers, especially in low-income countries where the mortality rate can exceed 60 percent.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
News Archive
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.
Sepsis presents a major challenge for health care providers, especially in low-income countries where the mortality rate can exceed 60 percent.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.
A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).
› Verified 8 days ago
Aeroflow Urology, Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2616 Sherwood Hall Ln, Alexandria, Virginia 22306 Phone: (888) 345-1780 | |
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5705 General Washington Dr, Alexandria, Virginia 22312 Phone: (703) 642-3141 | |
Giant Pharmacy #232 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5870 Kingstowne Ctr, Alexandria, Virginia 22315 Phone: (703) 313-8092 | |
Giant Pharmacy #261 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3131 Duke St, Alexandria, Virginia 22314 Phone: (703) 461-6199 | |
Giant Pharmacy #2742 Type: Medicare Supplier Location: 621e Glebe Rd, Alexandria, Virginia 22305 Phone: (703) 299-0471 |